Lupin's Alliance Partner Caplin Receives U.S. FDA Approval for Thiamine Hydrochloride Injection USP

Global pharma major Lupin Limited (Lupin) today announced that its alliance partner Caplin Steriles Limited (Caplin) has received final approval from the United States Food and Drug Administration (U.S.FDA) for its Abbreviated new Drug Application (ANDA) Thiamine Hydrochloride Injection USP, 200 mg/2 mL (100 mg/mL) Multiple-dose Vials, to market a therapeutically equivalent to the reference listed drug (RLD), Thiamine Hydrochloride Injection USP, 200 mg/2 mL (100mg/mL), of Fresenius Kabi USA LLC.

Thiamine Hydrochloride Injection USP had an annual sale of approximately USD 36 million in the U.S. (IQVIA MAT for the 12-month period ending December 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 646.20 as compared to the previous close of Rs. 657.20. The total number of shares traded during the day was 35204 in over 2448 trades.

The stock hit an intraday high of Rs. 653.70 and intraday low of 641.00. The net turnover during the day was Rs. 22750386.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 CaplinSteriles ANDA Approval USFDA ThiamineHydrochlorideInjectionUSP